[go: up one dir, main page]

WO1999061640A2 - Vecteur derive par aav - Google Patents

Vecteur derive par aav Download PDF

Info

Publication number
WO1999061640A2
WO1999061640A2 PCT/GB1999/001633 GB9901633W WO9961640A2 WO 1999061640 A2 WO1999061640 A2 WO 1999061640A2 GB 9901633 W GB9901633 W GB 9901633W WO 9961640 A2 WO9961640 A2 WO 9961640A2
Authority
WO
WIPO (PCT)
Prior art keywords
adeno
gene
producer cell
viral
associated viral
Prior art date
Application number
PCT/GB1999/001633
Other languages
English (en)
Other versions
WO1999061640A3 (fr
Inventor
Robert James Anderson
Hugh Grant Prentice
Ian Duncan Macdonald
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Publication of WO1999061640A2 publication Critical patent/WO1999061640A2/fr
Publication of WO1999061640A3 publication Critical patent/WO1999061640A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention relates to an improved adeno-associated viral vector, to a method of transfecting target cells, an adeno-associated viral producer cell and a method for the production of an adeno-associated viral vector.
  • Adeno-associated virus is a vector which has shown promise in virally-mediated gene therapy protocols.
  • AAV is a small, 20-22nm, replication defective, non-pathogenic parvo virus.
  • Six serotypes of AAV are currently known (types 1 to 6) , of which type 2 is the most extensively studied.
  • AAV type 2 has a single stranded DNA genome of 4.7kB which encodes both structral proteins through a cap gene and non-structural proteins through a rep gene.
  • the virus has a pair of 146bp inverted terminal repeats (ITRs) which are the only els acting elements in AAV required for replication and packaging.
  • ITRs inverted terminal repeats
  • the present invention aims to increase the level of transgene expression from an adeno-associated viral vector.
  • the present invention provides an adeno-associated viral vector containing a transgene and encapsidating a protein with adenovirus E4 ORF6 activity.
  • the protein is preferably an adenovirus E4 ORF6 protein such as is obtainable from adenovirus .
  • the present invention provides the adeno- associated viral vector for use as a medicament, especially in gene therapy. Also provided is a method for transfecting target cells, which comprises contacting target cells with the adeno-associated viral vector under conditions to achieve adeno-associated viral infection.
  • E4 ORF6 needs to be present as a polypeptide to facilitate conversion of the AAV single stranded genome to the double stranded replicative form.
  • the present invention provides an adeno- associated viral producer cell containing a gene encoding a protein with E4 ORF6 activity, which gene is under the control of an inducible promoter.
  • E4 0RF6 constitutive expression of E4 0RF6 in the AAV producer cell tends to have an adverse effect on the cell. This was unexpected. However, by putting the gene under control of an inducible promoter the producer cell is able to tolerate the presence of the protein.
  • Any inducible promoter may be used, such as the MMTV-LTR (Mouse Mammary Tumour Virus-Long Terminal Repeat) promoter, which is inducible by dexamethasone .
  • the inducer may be added to the medium in which the cells grow or, alternatively, may be produced upon infection of the cell by AAV or helper virus for AAV.
  • an AAV inducible promoter was used; the P5 promoter. In this case, upon infection with both adeno-virus and AAV, the P5 promoter is induced so as to induce the E4 ORF6 protein.
  • the gene comprises a drug-resistance marker, such as an antibiotic resistance marker which enables the cells to be grown in medium containing the relevant drug or antibiotic.
  • the selectable marker may be a cell surface marker such as a receptor which can be specifically targeted by a complimentary molecule such as an antibody thereto.
  • One such cell surface marker is nerve growth factor (NGF) .
  • the gene encoding adenovirus E4 ORF6 protein may be conveniently introduced into the producer cell on a plasmid.
  • the E4 ORF6 gene may be readily obtained from an adenovirus such as adenovirus type 2, which is deposited as ATCC VR846, the sequence of which is published by EMBL at locus HACG. See also Ohman et al in Virology 194 (1) , 50-58, 1993 where cloning of E4 ORF is reported. From the EMBL sequence the E4 region spans nucleotides 32801-35609 and E4 ORF6 from Ohman et al spans nucleotides 33193-34115 .
  • the protein with E4 ORF6 activity has a nuclear localisation sequence which is typically situated outside of the functional part of the E4 ORF6 protein, typically at or near the N- or C-terminal sequence of the protein.
  • the nuclear localisation sequence confers on the protein an important property.
  • the AAV producer cell which incorporates the gene encoding the protein with E4 ORF6 activity may be any producer cell commonly used to produce AAV vectors, such as a human 293 producer cell (ATCC CRL 1573) .
  • the AAV will be rep " cap " and so either a second transfection step involving the introduction of rep and cap on, for example, a plasmid would need to be undertaken or the producer cells would have to be made rep + cap + .
  • the producer cell is a stable cell containing rep and cap, both associated with a selectable marker as described above.
  • transfection or infection by AAV DNA (rep " cap " ) requires no second plasmid transfection step.
  • the producer cell comprises a rep-containing region which comprises a rep gene associated with a marker gene for rep, and a cap-containing region which comprises a cap gene associated with a marker gene for cap.
  • the rep-containing and cap-containing regions are preferably sufficiently spaced apart to prevent their simultaneous recombination with adeno-associated virus. This confers a further advantage on the viral producer cells .
  • the AAV DNA would necessarily contain inverted terminal repeats and so a problem arises in producing AAV vectors because there is a low but significant frequency of homologous recombination.
  • the AAV producer cells contain a rep gene contiguous with a cap gene, homologous recombination events result in contaminating amounts of wild-type AAV being formed. This problem is avoided where the cap and rep genes are spaced sufficiently apart to prevent such simultaneous co- recombination of rep and cap.
  • the rep gene and/or the cap gene is plasmid-borne so as to avoid contaminating homologous recombination. More preferably, both rep and cap genes are plasmid-borne.
  • the viral producer cell is formed from a multicopy plasmid which carries a rep gene and cap gene. In this embodiment it is preferable for the plasmid to have an origin of replication.
  • the producer cell is preferably capable of producing a replication initiator for the origin of replication of the plasmid. In this way, multiple copies of the plasmid are made in the cell.
  • Various combinations of replication initiator and origin of replication are known. A particularly useful combination is where the cell is a COS cell and the origin of replication is SV40 ori .
  • COS cells produce T antigen as a replication initiator for SV40 ori.
  • Another example of such a combination is EBNA1 as a replication initiator for oriP.
  • EBNA1 and oriP are derived from the Epstein Barr virus which is capable of infecting a variety of cells, including human cell lines.
  • the rep gene encodes a rep mRNA which has reduced efficiency of translation as compared with wild-type rep mRNA. More preferably, the rep mRNA of the viral producer cells has a mutant initiation codon which reduces the efficiency of translation. Wild-type initiation codons are AUG whereas mutant initiation codons may be UUG, CUG, or GUG, preferably ACG.
  • the adeno-associated viral producer cell comprises at least one rep gene and at least two cap genes, wherein the number of cap genes exceeds the number of rep genes . This may be achieved by locating a rep gene on one plasmid and locating a cap gene on a multicopy plasmid.
  • the present invention provides a method for the production of an adeno-associated viral vector, which comprises introducing into the viral producer cell DNA comprising a transgene flanked by adeno-associated virus inverted terminal repeats, allowing formation of adeno- associated viral vectors in the viral producer cell, and isolating the adeno-associated viral vectors.
  • the DNA may be introduced into the producer cell by transfection, for example as part of a suitable plasmid, in the presence of an adeno- associated helper virus, or by infection as part of a suitable virus.
  • the DNA may be integrated into the genome of an adeno- associated helper virus which infects the producer cell or the DNA may comprise the genome of an adeno-associated virus which is infected into the producer cell in the presence of an adeno-associated helper virus.
  • the helper virus comprises an adenovirus, such as adenovirus type 5.
  • This example compares level of transgene expression in target cells using AAV type 2 viruses from producer cell lines containing E4 0RF6 with and without an NLS .
  • a stable cell line was made by lipofecting COS 7 cells (ATCC CRL 1651) with the E4 ORF6 containing plasmid containing a hygromycin resistance cassette.
  • Adenovirus E40RF6 cDNA was a very kind gift from Gorkan Akusvardi.
  • the cDNA was excised from pBR322 using BamHI and inserted into pBK-CMV (Stratagene) to give pCMV-ORF6.
  • the ORF6 cDNA was then subcloned into the hygromycin resistant expression plasmid p3"SS (Stratagene) by digestion with Hind III/XbaI and subsequent ligation to Hind III/XbaI digested p3"SS. This gave p3"SS/ORF6.
  • NLS nuclear localisation signal
  • Hygromycin resistant stable COS-7 cell transfectant lines were created using both the above plasmids to give lines termed COS/ORF6/NLS and COS/ORF6.
  • rAAV Three different aliquots of rAAV were prepared, one prepared using the C0S/0RF6/NLS cell line, one using COS/ORF6 and one using unmodified parental COS cells.
  • Helper and Vector Plasmids pUC 18 was modified by the insertion of a pair of linkers:- 5' CAT CGA TGG CCA GAT CTG ATA TCG ATG 3 ' and 5 ' CAT GGT AGC TAC CGG TCT AGA CTA TAG CTA CCT AG 3 ' between the Kpn I /Bam HI sites to give an extended multiple cloning site with additional Cla I, Bal I, Bgl II, and Eco RV sites. Wild type
  • AAV was obtained from the ATCC. After digest with Bgl II, the resulting AAV fragment was cloned into the modified pUC18 to give pUC/AAV.
  • Dra III and Nco I Digestion of pUC/AAV with Dra III and Nco I removes the two genes rep and cap, essentially leaving the ITRs of the wild type virus . Blunting the Dra III/Nco I ends with T4 DNA polymerase allows ligation of the ⁇ -galactosidase cDNA plasmid (Promega) to yield pUC/AAV/ ⁇ -gal (vector plasmid) .
  • the ITR helper plasmid was obtained by sequential removal of the ITRs from pUC/AAV. The 5' ITR was removed by digestion with Eco RV and SnaBI and religating the DNA. This plasmid was then digested with Bal I to remove the 3 ' ITR and religated to give pUC/rep/cap. (helper plasmid) .
  • AAV ⁇ - galactosidase AAV ⁇ -gal
  • helper plasmid 3:1 ratio of helper to vector plasmid
  • the COS cells were washed twice with HBSS and after the final aspiration the DNA/lipofectin mixture was layered onto the cells with fresh Opti-MEM to ensure the cells were adequately covered.
  • the COS cells were then incubated for 5 hours at 37°C and 5% C0 2 , after which the serum free medium was replaced with fresh DMEM containing 10% FCS and adenovirus type 5 at a multiplicity of infection (MOI) of 5. Incubation was then continued until full cytopathic effect of the adenovirus was seen, typically after 48 to 72 hours.
  • the infected cells were scraped off and collected together with the supernatant. Trypsin was added to a final concentration of 0.02% and deoxycholate to a final concentration of 0.5%.
  • the sample was then incubated at 37°C for 2 hours and then subjected to three cycles of freeze- thawing to release any virus remaining within the cells. Following the final freeze cycle, the sample was incubated at 56°C for 1 hour to inactivate the heat-labile adenovirus. The sample was spun at 2100 xG for 10 minutes to pellit the cellular debris and the supernatant containing the recombinant AAV was decanted into a separate 50ml tube (Falcon) .
  • the concentrated viral preparation was desalted using a Pharmacia Biotech pD-10 Sephadex desalt column. The desalted viral preparation was then further concentrated using a Centriprep 30 concentrator to give a final volume of approximately 500 ⁇ l.
  • the viral sample Prior to infecting cells, the viral sample was sterilised free of bacteria using a 0.2 ⁇ m filter (Sartorius - Centrisart C4). The viral concentrate was then either analysed immediately, used to infect target cells or stored at -70°C.
  • Viral titre was quantitated using a dot-blot assay as follows. Hybond-N nylon membrane (Amersham-Life Science) was prewetted in 6x SSC, and then inserted in the dot blot apparatus (Bio- Rad) .
  • the reference control DNA and the recombinant AAV preparation were diluted in lOx SSC to the following ratios, neat, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024 and 1:2048 and immediately prior to loading, the samples were denatured by heating at 100°C for 5 minutes. The samples were then loaded onto the nylon membrane and sucked through under negative pressure. The nylon filter was then removed from the dot blot apparatus and dried by incubation for 2 hours at 80°C. After drying both sides of the filter were UV irradiated (Stratagene UV Stratalinker) .
  • Prehybridisation buffer (24 mis 20x SSC, 8 mis 50x Denharts, 4mls 10% SDS, 80 ⁇ l (lOng/ml) salmon sperm DNA) , was warmed to 60°C and added to the filter present in a hybridisation bottle. Prehybridisation was allowed to continue for 4 hours at 65°C. After this time, the prehybridisation buffer was then discarded and replaced with hybridisation buffer (9 mis 20x SSC, 3mls 50x Denharts, 1.5mls 10% SDS, 300 ⁇ l EDTA 0.5M, 30 ⁇ l salmon sperm DNA (lOng/ml) , 16.2ml H 2 0) containing a radiolabelled probe.
  • the probe used was the CMV promoter present in both the viral preparation and the reference plasmid.
  • the CMV promoter probe was radiolabelled using the rediprime DNA labelling system (Amersham Life Science) following the manufacturers instructions. After the labelling reaction had completed, unincorporated radio- label was removed using a Qiagen desalt column following the manufacturers instructions.
  • the probe Prior to the addition of the probe to the hybridisation mix and the filter, the probe was denatured by heating to 100°C for 5 minutes. Hybridisation was allowed to proceed for 18 hours at 65°C. Post hybridisation, the filter was washed twice in 2x SSC and 0.1% SDS at 37°C for 10 minutes, followed by two washes in 2x SSC and 0.1% SDS at 65°C for 10 minutes.
  • ⁇ -galactosidase activity was assayed in the virally infected cells as follows. The medium was carefully aspirated from the infected cells and the cells were then washed twice with PBS buffer (137mM NaCl, 2.7mM KCl, 4.3mM Na 2 HP0 4 , 1.47mM KH 2 P0 4 , pH 7.1) . After washing 400 ⁇ l of Reporter Lysis Buffer (Promega) was added to each cell population, the cells were incubated with the lysis buffer for 15 minutes at room temperature. The cells were then carefully scraped off from each well and transferred to separate microcentrifuge tubes. Each tube was vortexed for 15 seconds and centrifuged at 13,000rpm for 2 minutes. After this the supernatants were transferred to fresh microcentrifuge tubes.
  • PBS buffer 137mM NaCl, 2.7mM KCl, 4.3mM Na 2 HP0 4 , 1.47mM KH 2 P0 4 , pH 7.1
  • Target cells were assessed as being positive after incubation with ONPG as described above .
  • This Example demonstrates construction of a COS Cell Line capable of improving AAV-type 2 titre.
  • This cell line is suitable for use in the present invention as a vehicle for a gene encoding E40RF6.
  • a cell line containing multiple copies of the AAV cap gene was created as follows.
  • pUC 18 was modified by the insertion of a pair of linkers:- 5' CAT CGA TGG CCA GAT CTG ATA TCG ATG 3 ' and 5 ' CAT GGT AGC TAC CGG TCT AGA CTA TAG CTA CCT AG 3 ' between the Kpn I/Bam HI sites to give an extended multiple cloning site with additional Cla I, Bal I, Bgl II, and Eco RV sites. Wild type
  • AAV was obtained from the ATCC. After digest with Bgl II, the resulting AAV fragment was cloned into the modified pUC18 to give pUC/AAV.
  • the AAV cap gene was excised from pUC/AAV by digestion with SnaBI and HinD III and ligated into HinD III/ Sma I digested pBK-CMV (Stratagene) to yield pCMV-cap.
  • a COS cell stable transfectant cell line was created by introducing 2 ⁇ g pCMV-cap DNA into exponentially growing COS cells using Lipofectin following the manufacturers' instructions. This gave COS/cap.
  • p3 ' SS (Stratagene) was digested with Pfl MI and Nsi I to release a 1.8kbp Hygromycin resistance cassette. This was blunted with T4 DNA polymerase.
  • the AUG initiation codon of rep68/78 in pUC/AAV/Neo was mutated by standard techniques to give an ACG codon. This was verified by sequencing.
  • This construct was digested with Apa I and Nde I to remove the cap gene and the ends blunted with T4 DNA polymerase.
  • the hygromycin cassette was ligated to the mutated rep gene cassette to give pUC/ACGrep/Hygro.
  • COS cell stable transfectant cell line was created by introducing 2 ⁇ g pUC/ACGrep/Hygro DNA into exponentially growing COS/cap cells using Lipofectin following the manufacturers' instructions. This gave COS/rep/cap.
  • COS/rep/cap or COS/cap or parental COS cells were grown to 80% confluency in 92mm tissue culture plates (Nunclon) in DMEM supplemented with 10% FCS.
  • 4.6 ⁇ g of AAV ⁇ -galactosidase (AAV ⁇ -gal) and in the case of parental COS cells, 9.4 ⁇ g of rep/cap plamid were addded to a 17 x 120mm conical polystyrene sterile tube (Falcon) , together with lOO ⁇ l of serum free medium (Opti- MEM - Life Sciences) .
  • 56 ⁇ l of lipofectin was added to a second polystyrene tube together with another lOO ⁇ l of Opti-MEM.
  • the DNA/lipofectin mixture was mixed gently and incubated for 15 minutes at room temperature.
  • the cells were washed twice with HBSS and after the final aspiration the DNA/lipofectin mixture was layered onto the cells with fresh Opti-MEM to ensure the cells were adequately covered.
  • the cells were then incubated for 5 hours at 37°C and 5% C0 2 , after which the serum free medium was replaced with fresh DMEM containing 10% FCS and adenovirus type 5 at a multiplicity of infection (MOI) of 5. Incubation was then continued until full cytopathic effect of the adenovirus was seen, typically after 48 to 72 hours.
  • MOI multiplicity of infection
  • the infected cells were scraped off and collected together with the supernatant. Trypsin was added to a final concentration of 0.02% and deoxycholate to a final concentration of 0.5%. The sample was then incubated at 37°C for 2 hours and then subjected to three cycles of freeze-thawing to release any virus remaining within the cells. Following the final freeze cycle, the sample was incubated at 56°C for 1 hour to inactivate the heat-labile adenovirus. The sample was spun at 2100 xG for 10 minutes to pellet the cellular debris and the supernatant containing the recombinant AAV was decanted into a separate 50ml tube (Falcon) .
  • Falcon 50ml tube
  • the concentrated viral preparation was desalted using a Pharmacia Biotech pD-10 Sephadex desalt column. The desalted viral preparation was then further concentrated using a Centriprep 30 concentrator to give a final volume of approximately 500 ⁇ l.
  • the viral sample Prior to infecting cells, the viral sample was sterilised free of bacteria using a 0.2 ⁇ m filter (Sartorius - Centrisart C4). The viral concentrate was then either analysed immediately, used to infect target cells or stored at -70°C.
  • Viral titre was quantitated using a dot-blot assay as follows. Hybond-N nylon membrane (Amersham-Life Science) was prewetted in 6x SSC, and then inserted in the dot blot apparatus (Bio- Rad) .
  • the reference control DNA and the recombinant AAV preparation were diluted in lOx SSC to the following ratios, neat, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024 and 1:2048 and immediately prior to loading, the samples were denatured by heating at 100°C for 5 minutes. The samples were then loaded onto the nylon membrane and sucked through under negative pressure. The nylon filter was then removed from the dot blot apparatus and dried by incubation for 2 hours at 80°C. After drying both sides of the filter were UV irradiated (Stratagene UV Stratalinker) .
  • Prehybridisation buffer (24 mis 20x SSC, 8 mis 50x Denharts, 4mls 10% SDS, 80 ⁇ l (lOng/ml) salmon sperm DNA) , was warmed to 60°C and added to the filter present in a hybridisation bottle. Prehybridisation was allowed to continue for 4 hours at 65°C. After this time, the prehybridisation buffer was then discarded and replaced with hybridisation buffer (9 mis 20x SSC, 3mls 50x Denharts, 1.5mls 10% SDS, 300 ⁇ l EDTA 0.5M, 30 ⁇ l salmon sperm DNA (lOng/ml) , 16.2ml H 2 0) containing a radiolabelled probe.
  • the probe used was the CMV promoter present in both the viral preparation and the reference plasmid.
  • the CMV promoter probe was radiolabelled using the rediprime DNA labelling system (Amersham Life Science) following the manufacturers' instructions. After the labelling reaction had completed, unincorporated radio-label was removed using a Qiagen desalt column following the manufacturers instructions.
  • the probe Prior to the addition of the probe to the hybridisation mix and the filter, the probe was denatured by heating to 100°C for 5 minutes. Hybridisation was allowed to proceed for 18 hours at 65°C. Post hybridisation, the filter was washed twice in 2x SSC and 0.1% SDS at 37°C for 10 minutes, followed by two washes in 2x SSC and 0.1% SDS at 65°C for 10 minutes.
  • Titres of virus, as determined by the viral dot-blot, obtained from the COS rep/cap cells were higher than those obtained using parental cells and the two plasmid system. No virus was produced from the COS/cap cells .
  • the results are set out in Table 2.
  • All titres refer to the number of genomes obtained per ml. of virus as assessed by dot-blot hybridisation.
  • a gene encoding E40RF6 may be incorporated into this improved COS cell line, as described above.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention a trait à un vecteur viral adéno-associé contenant un transgène et encapsidant une protéine à activité de type adénovirus E4 ORF6.
PCT/GB1999/001633 1998-05-22 1999-05-21 Vecteur derive par aav WO1999061640A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9811171.9 1998-05-22
GBGB9811171.9A GB9811171D0 (en) 1998-05-22 1998-05-22 Viral vector

Publications (2)

Publication Number Publication Date
WO1999061640A2 true WO1999061640A2 (fr) 1999-12-02
WO1999061640A3 WO1999061640A3 (fr) 2000-01-27

Family

ID=10832634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001633 WO1999061640A2 (fr) 1998-05-22 1999-05-21 Vecteur derive par aav

Country Status (2)

Country Link
GB (1) GB9811171D0 (fr)
WO (1) WO1999061640A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10056210A1 (de) * 2000-11-13 2002-05-29 Arimedes Biotechnology Gmbh Virales Expressionssystem
WO2003104467A1 (fr) * 2002-04-25 2003-12-18 Crucell Holland B.V. Moyens et procede de production de vecteurs d'adenovirus
US8912142B2 (en) 2009-04-01 2014-12-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Method of regulating proliferation and differentiation of keratinocyes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
JPH11514853A (ja) * 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたａａｖベクター

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10056210A1 (de) * 2000-11-13 2002-05-29 Arimedes Biotechnology Gmbh Virales Expressionssystem
WO2003104467A1 (fr) * 2002-04-25 2003-12-18 Crucell Holland B.V. Moyens et procede de production de vecteurs d'adenovirus
EA010828B1 (ru) * 2002-04-25 2008-12-30 Круселл Холланд Б.В. Рекомбинантный аденовирусный вектор и способы его получения и применения
US8912142B2 (en) 2009-04-01 2014-12-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Method of regulating proliferation and differentiation of keratinocyes

Also Published As

Publication number Publication date
WO1999061640A3 (fr) 2000-01-27
GB9811171D0 (en) 1998-07-22

Similar Documents

Publication Publication Date Title
US8409842B2 (en) Recombinant adeno-associated virus production
US6943019B2 (en) Methods and vector constructs useful for production of recombinant AAV
EP1127150B1 (fr) Sequences d'acide nucleique du serotype i du virus associe aux adenovirus, vecteurs et cellules hotes contenant ces derniers
Grimm et al. Novel tools for production and purification of recombinant adenoassociated virus vectors
US8637255B2 (en) Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same
AU699973B2 (en) Recombinant viral vector system
US20040087026A1 (en) Host cells for packing a recombinant adeno-associated virus (raav), method for the production and use thereof
CA2359748A1 (fr) Procede de fabrication d'un virus adeno-associe recombine, moyens adaptes a cette fabrication et utilisation dudit virus pour la fabrication d'un medicament
US20020064878A1 (en) Compositions and methods for recombinant adeno-associated virus production
CZ230697A3 (en) Cells for producing recombinant adenoviruses
WO1996036364A9 (fr) Systeme de vecteur viral de recombinaison
JP2001500015A (ja) Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US20070202587A1 (en) Recombinant AAV production in mammalian cells
CA2397532A1 (fr) Systemes d'encapsidation pour aav recombinant
NZ562881A (en) High titer recombinant AAV production
US20040014031A1 (en) Inducible highly productive rAAV packaging cell-lines
JP2024525121A (ja) 高レベルｒＡＡＶ生産のためのシステム
Shull et al. Genomic clones of bovine parvovirus: construction and effect of deletions and terminal sequence inversions on infectivity
US20070275449A1 (en) Method for Large-Scale Production, Isolation, Purification and the Uses of Multi-Type Recombinant Adeno-Associated Virus Vectors
WO1999061640A2 (fr) Vecteur derive par aav
EP1845163A2 (fr) Séquences d'acides nucléiques de sérotype 1 du virus associé à l'adénovirus
WO2003084977A1 (fr) Systeme de regulation de l'expression genique et son utilisation dans les lignees cellulaires d'incorporation de virus recombinants
US7037723B1 (en) Recombinant herpes viruses for preparing recombinant adeno-associated viruses
CN119894919A (zh) 包含来自三种不同辅助病毒的辅助元件的嵌合辅助核酸分子
WO1999061641A1 (fr) Production de vecteur-aav (virus adeno-associe)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase